Streetbeat News

Products Services

KTRA

Kintara Therapeutics Inc's stock has dropped by 69.2% after the company announced that their drug VAL-083 did not outperform existing treatments for glioblastoma. As a result, the company is discontinuing the development of VAL-083 and shifting focus to REM-001, a localized tumor treatment. Kintara will also explore strategic options to maximize shareholder value. Further data on VAL-083 is expected in 2024, while a study for REM-001 in cutaneous metastatic breast cancer is planned for the end of 2023.

Portfolio Pulse from Henry Khederian

October 31, 2023 | 1:21 pm

CGEN

Compugen Ltd. (NASDAQ:CGEN) will present new data on its lead pre-clinical asset COM503, a potential first-in-class anti-IL18BP antibody, at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) in November 2023. The data suggests that COM503 has a leading edge in inhibiting tumor growth while avoiding peripheral toxicity associated with administration of a cytokine. The company plans to file an IND in 2024.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2023 | 1:20 pm

KTRA

Kintara Therapeutics announced preliminary topline results from the GBM AGILE study, indicating that VAL-083 did not outperform current standards of care in glioblastoma. This news led to a decrease in the company's share price.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2023 | 1:20 pm

IOVA

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) has announced the publication of abstracts for poster presentations reporting clinical data and trial design for tumor infiltrating lymphocyte (TIL) therapies at the Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting. The data includes a four-year analysis of pooled Cohorts 2 and 4 of the C-144-01 trial, which reports the longest follow-up data on lifileucel treatment outcomes in patients with anti–PD-1–refractory advanced melanoma treated with TIL therapy.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2023 | 1:20 pm

AKYA

Akoya Biosciences will showcase its new Spatial Biology 2.0 solutions and spatial phenotyping data at SITC 2023. The new PhenoCycler-Fusion 2.0 and PhenoImager HT 2.0 platforms offer advancements in speed and scale for spatial biology research. The company's global network of CROs providing Akoya's spatial phenotyping solutions will also exhibit at SITC.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2023 | 1:19 pm

INDP

Indaptus Therapeutics, Inc. (NASDAQ:INDP) will present interim data from the first cohort of its Phase 1 INDP-D101 trial of Decoy20 at the Society for Immunotherapy of Cancer (SITC) on November 4, 2023. The data showed that each of the first cohort participants experienced transient activation of biomarkers associated with immune responses and expected transient adverse events, both associated with rapid clearance of Decoy20. The company is encouraged by the tolerability of Decoy20 and the evidence for broad immune biomarker activation.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2023 | 1:18 pm

KTRA

Kintara Therapeutics (NASDAQ:KTRA) announced that its GBM AGILE study showed that VAL-083 did not perform better than the current standards of care in glioblastoma. As a result, the company is suspending the development of VAL-083 and shifting its focus to its REM-001 program and other strategic opportunities. The company also plans to conduct a review of potential strategic opportunities to maximize shareholder value. Kintara expects to enroll the first subject in a 15-patient CMBC study around the end of 2023, which is expected to be covered by a $2 million grant from the NIH.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2023 | 1:18 pm

MU

Micron Technology, Inc. (NASDAQ:MU) has announced the availability of the Crucial T500 Gen4 NVMe SSD, an expansion of its NVMe solid-state drive portfolio. The T500 SSD leverages Micron's advanced 232-layer 3D NAND technology and offers up to a 40% higher performance-to-power ratio and speeds that are two times faster than the previous Gen3 NVMe SSD offering. The T500 SSD is available in two options, with and without a heatsink, and is designed for platforms like the PlayStation 5 and PC gaming rigs, as well as laptops, desktops, and workstations.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2023 | 1:17 pm

AMZN

DV

DoubleVerify (DV), a digital media measurement, data, and analytics software platform, has expanded its measurement coverage for advertisers using Twitch inventory and Amazon custom audiences in Amazon DSP through a server-to-server integration. DV is the first third-party measurement provider to offer Amazon DSP advertisers comprehensive media quality and performance solutions to measure and optimize ads served to Amazon custom audiences. Advertisers can also launch DV's measurement solutions across inventory available on Twitch.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2023 | 1:16 pm

FUBO

LGF.A

WHR

FuboTV Inc. (FUBO) has announced a partnership with TiiCKER, a shareholder loyalty and engagement platform. The partnership will provide Fubo shareholders with a tiered perks program, including a 20% discount on a one-month subscription to Fubo Pro for new subscribers and exclusive early access to product features. TiiCKER also partners with Lionsgate (LGF.A, LGF.B), Whirlpool (WHR), Real Good Foods (RGF), and Mondee (MOND).

Portfolio Pulse from Benzinga Newsdesk

October 31, 2023 | 1:15 pm